Man­u­fac­tur­ing roundup: mR­NA man­u­fac­tur­er nets $300M+ in­vest­ment to scale re­search; Cy­ti­va ac­quires Michi­gan fa­cil­i­ty

As mR­NA tech has been made more pop­u­lar by the Covid-19 pan­dem­ic, in­vestor cash is mak­ing its way to man­u­fac­tur­ers and re­searchers.

In their lat­est move, Irish biotech Nor­max Bio­med has net­ted a €300 Mil­lion, or $305 mil­lion, in­vest­ment from pri­vate firm GEM Glob­al Yield.

The deal will see GEM pro­vide Nor­max with a share sub­scrip­tion fa­cil­i­ty of up to €50 Mil­lion for a 36-month term fol­low­ing the pub­lic list­ing of the Nor­max com­mon stock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER